Logo image of ALTME.PA

TME PHARMA NV (ALTME.PA) Stock Fundamental Analysis

EPA:ALTME - Euronext Paris - Matif - NL0015000YE1 - Common Stock - Currency: EUR

0.0702  0 (-2.9%)

Fundamental Rating

2

Taking everything into account, ALTME scores 2 out of 10 in our fundamental rating. ALTME was compared to 72 industry peers in the Biotechnology industry. ALTME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALTME does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALTME has reported negative net income.
ALTME had a negative operating cash flow in the past year.
ALTME had negative earnings in each of the past 5 years.
ALTME had a negative operating cash flow in each of the past 5 years.
ALTME.PA Yearly Net Income VS EBIT VS OCF VS FCFALTME.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

ALTME's Return On Assets of -214.99% is on the low side compared to the rest of the industry. ALTME is outperformed by 81.94% of its industry peers.
The Return On Equity of ALTME (-403.64%) is worse than 70.83% of its industry peers.
Industry RankSector Rank
ROA -214.99%
ROE -403.64%
ROIC N/A
ROA(3y)-235.68%
ROA(5y)-170.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTME.PA Yearly ROA, ROE, ROICALTME.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K 1.5K 2K

1.3 Margins

ALTME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTME.PA Yearly Profit, Operating, Gross MarginsALTME.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALTME has more shares outstanding
ALTME has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALTME has an improved debt to assets ratio.
ALTME.PA Yearly Shares OutstandingALTME.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALTME.PA Yearly Total Debt VS Total AssetsALTME.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

ALTME has an Altman-Z score of -95.64. This is a bad value and indicates that ALTME is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -95.64, ALTME is not doing good in the industry: 87.50% of the companies in the same industry are doing better.
There is no outstanding debt for ALTME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -95.64
ROIC/WACCN/A
WACCN/A
ALTME.PA Yearly LT Debt VS Equity VS FCFALTME.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

ALTME has a Current Ratio of 2.11. This indicates that ALTME is financially healthy and has no problem in meeting its short term obligations.
ALTME has a Current ratio (2.11) which is in line with its industry peers.
ALTME has a Quick Ratio of 2.11. This indicates that ALTME is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.11, ALTME is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 2.11
ALTME.PA Yearly Current Assets VS Current LiabilitesALTME.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

ALTME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.82%, which is quite impressive.
EPS 1Y (TTM)86.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.24% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.21%
EPS Next 2Y23.5%
EPS Next 3Y12.24%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTME.PA Yearly Revenue VS EstimatesALTME.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100K 200K 300K
ALTME.PA Yearly EPS VS EstimatesALTME.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTME. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTME.PA Price Earnings VS Forward Price EarningsALTME.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTME.PA Per share dataALTME.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

ALTME's earnings are expected to grow with 12.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.5%
EPS Next 3Y12.24%

More info and screens

0

5. Dividend

5.1 Amount

ALTME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TME PHARMA NV

EPA:ALTME (3/7/2025, 7:00:00 PM)

0.0702

0 (-2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.6%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.61M
Analysts86
Price Target0.4 (469.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-90%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.22
P/tB 4.23
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -214.99%
ROE -403.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-235.68%
ROA(5y)-170.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.31%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.11
Quick Ratio 2.11
Altman-Z -95.64
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.77%
Cap/Depr(5y)31.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.1%
EPS Next Y71.21%
EPS Next 2Y23.5%
EPS Next 3Y12.24%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60%
EBIT Next 3Y-24.4%
EBIT Next 5YN/A
FCF growth 1Y59.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.55%
OCF growth 3YN/A
OCF growth 5YN/A